[Expression of MAGE-3 gene product in non-small cell lung cancer].
To study the expression of MAGE-3 antigen in non-small cell lung cancer (NSCLC). The expression of MAGE-3 antigen was examined in formalin fixed, paraffin embedded sections of NSCLC by LSAB immunohistochemical technique. MAGE-3 antigen was detected in 31 of 104 (29.8%) patients with primary NSCLC. The frequency of MAGE-3 expression was significantly correlated to the absence of metastasis (P < 0.05) and better survival rate (P < 0.01). There was no significant relationship between MAGE-3 expression and histological type of NSCLC. MAGE-3 antigen expression in NSCLC correlates with better prognosis. It is a candidate molecular target for specific immunotherapy for NSCLC patients.